fromFortune Europe3 weeks agoNew London IPOs hit 28-year low amid AstraZeneca exit concernsLondon's IPO volume is at its slowest half-year since 1997, highlighting a significant concern regarding its market appeal alongside a potential AstraZeneca US listing.London politics